In addition, patients with cancer, such as epidermal growth factor receptor-mutated nonsmall cell lung cancer or B-Raf proto-oncogene, serine/threonine kinase (BRAF)-mutated melanoma, inevitably acquire drug resistance after long-term treatment [5, 6]. The gene discussed is BRAF; the disease is lung cancer.